World Pharmaceutical Market Summary

Información y noticias suministradas por IMS que incluyen un resumen del Mercado Farmacéutico Mundial (12 meses acumulados a Octubre-2003).

LATEST ARTICLES
LATIN AMERICA LAGGING BEHIND IN HEALTHCARE PROVISION : Lack of access to healthcare for large segments of the population is still a major problem in Latin America... http://open.imshealth.com/IMSinclude/i_article_20040105.asp
SCAPEGOAT OR SAVIOUR? THE DUAL ROLE OF THE PHARMACEUTICAL INDUSTRY IN THE WAR AGAINST HIV/AIDS : After an unusually high-profile World AIDS Day in December, IMS looks at the current situation and the global pharmaceutical industry's response... http://open.imshealth.com/IMSinclude/i_article_20040105a.asp
WORLD SALES THROUGH RETAIL PHARMACIES*  (Twelve months to October 2003).
NORTH AMERICA$167.9billion, up 10% = United States $159.4billion, up 10% - Canada $8.5billion, up 12%.
EUROPE (leading 5)$72.2billion, up 6% = Germany $21.3billion, up 6% - France $17.7billion, up 5% - United Kingdom $12.5billion, up 9% - Italy $12.3billion, up 2% - Spain $8.4billion, up 12%.
JAPAN (including hospitals)$51.1billion, up 3%.
LATIN AMERICA (leading 3)$11.4billion, down 1%*
Mexico $6.1billion, up 1%* - Brazil $3.9billion, down 4%* - Argentina $1.5billion, up 3%*.
AUSTRALIA/NEW ZEALAND$4.0billion, up 7%.
More information, including sales by broad therapeutic categories for each country, is available free to download if you follow this link: http://open.imshealth.com/download/oct2003.pdf ** . Other detailed reports on pharmaceutical products, companies and therapeutic area sales are available from IMS HEALTH's online store at http://open.imshealth.com/ .
COMPANY NEWS IN BRIEF FOR DECEMBER
PFIZER offered a 54% premium to buy cardiovascular specialist ESPERION for $1.3 billion in the hopes of gaining a second cholesterol blockbuster. CSL finally signed the deal to acquire AVENTIS BEHRING, while RANBAXY is to buy Aventis' French generics unit, RPG. NOVARTIS will acquire BRISTOL-MYERS SQUIBB's Mead Johnson adult medical nutrition business, and RECORDATI is negotiating two deals, one in the EU and one in Eastern Europe. ANDRX will develop and market TEVA's generic oral contraceptives in North America, while IVAX and GEDEON RICHTER will collaborate on new generics for the US. SANTEN licensed JOHNSON & JOHNSON rights to three ophthalmic products in the US, and GLAXOSMITHKLINE exercised its option to BIOVAIL's Wellbutrin XL once-daily antidepressant. SHIRE will not establish a direct presence in Japan, and instead licensed kidney drug Fosrenol to BAYER's local unit. ROCHE/GENENTECH granted affiliate CHUGAI Japanese rights to two cancer antibodies, Avastin and Omnitarg, and TAKEDA will co-develop and market LILLY's drug for diabetic complications in the country. MERCK & CO began a number of alliances, including with ACTELION for renin inhibitors, a new class of antihypertensives, while Novartis and SKYEPHARMA will co-develop a new product for asthma and COPD. As expected, Pfizer returned the rights to CELLTECH's anti-TNF antibody, and the UK biotech is now selecting a new partner. In the US, J&J launched its long-acting antipsychotic, Risperdal Consta, while Chugai introduced Roche's Pegasys for hepatitis C in Japan. Risperdal was cleared in the US for use in bipolar mania, while FOREST and LUNDBECK's Lexapro was approved for use in generalised anxiety disorder. The FDA also approved Symbyax, Lilly's Prozac/Zyprexa combination, for bipolar depression, MYLAN's Ertaczo cream for tinea pedis, which will be marketed by J&J, and SERONO's Zorbtive for short bowel syndrome. Novartis' transplant drug Certican completed EU approval, as did SCHERING AG's rosacea treatment Finacea. France granted the first clearance for ASTRAZENECA's antithrombotic Exanta, while MERCK KGaA received the first approval for IMCLONE's colorectal cancer drug Erbitux from Switzerland.  New US guidelines warned that patients with heart failure should avoid the glitazones, GSK's Avandia, and Takeda/Lilly's Actos. J&J halted trials of anaemia therapy Procrit due to blood clots, and the EU is monitoring hexavalent vaccines from Aventis and GSK. ALTANA and Pfizer delayed the filing of asthma and COPD drug roflumilast in the EU, while J&J said it would need additional data before submitting AP-48, its new transdermal fentanyl system. SEPRACOR discontinued development of tecastemizole for allergic rhinitis. SCHERING-PLOUGH announced further cost-cutting measures, including a 10% reduction in payroll expenses, but CEO Fred Hassan put his money where his mouth is and bought $4.7m worth of company stock. Bayer is closing its Japanese R&D centre and laying off 190 scientists in California, ELAN sold its European sales and marketing business, and Aventis is seeking to improve efficiency. WATSON and J&J both received subpoenas relating to their US marketing activities. Elan sought arbitration over its Alzheimer's R&D alliance with Pfizer, while the latter followed J&J's example and said US wholesalers would have to buy its products direct from the company, in what was described as an attempt to reduce counterfeiting. But it was the season of goodwill... GSK and BOEHRINGER INGELHEIM both extended generic licences for cheap copies of their HIV drugs in South Africa, while Novartis signed an agreement with the WHO to provide free TB drugs for 500,000 patients.
*Source: IMS HEALTH. Growth rates are calculated at a constant exchange rate, (i.e. at the local currency level) with the exception of the Latin American markets. The unique system in Japan reduces the importance of the pharmacy in the distribution chain - sales for Japan include hospital data. For the USA, retail, foodstore and mail order pharmacy channels are included. In other countries sales monitored are limited to retail pharmacies only. **To view this file you will need the Adobe Acrobat Reader which is free from http://www.adobe.com/products/acrobat/readstep2.html If you have difficulty viewing this file please reply to this message stating the exact problem you are experiencing - there are known bugs using Internet Explorer 4 and Windows NT together with pdf files. We have also been made aware of printing problems using Acrobat Reader v3.0. We recommend you use the latest version of Acrobat Reader.